As Canadian cannabis king Tilray Brands, Inc. (NASDAQ:TLRY) prepares to report its fiscal Q2 2026 results on Thursday, the company stands at a crossroads. 

• TLRY stock is moving. See the chart and price action here. 

After years of regulatory stagnation, President Donald Trump signed an executive order in December to speed the rescheduling of marijuana to a Schedule III substance. However, Tilray struggles to turn a profit. 

Investors will be watching the company's Q2 earnings release closely for signs of financial hope. They will also be listening for commentary on rescheduling, tax relief and the new Tilray Medical USA subsidiary. 

Read Next: What To Expect At CES 2026: Nvidia, AMD, Joby, Archer, D-Wave And More

Rescheduling and 280E Relief

Tilray investors are optimistic about the DEA's expedited progress on reclassifying cannabis from Schedule I to Schedule III, as Trump's December directive to federal agencies has effectively cleared the path for the removal of the Section 280E tax burden. 

For Tilray, this could be a fundamental shift in profitability as cannabis operators have been barred from deducting standard business expenses, often resulting in effective tax rates exceeding 70%. 

Marijuana moving to Schedule III allows Tilray to treat its U.S. operations with the same fiscal standard as traditional firms, potentially unlocking millions in annual cash flow.

Tilray Medical USA: The US Entry Strategy

Tilray officially launched Tilray Medical USA in late December in direct response to the promised federal policy shift.  

The new subsidiary represents Tilray's move to transition from a diversified lifestyle brand to a serious medical pharmaceutical contender in the U.S. market. 

By leveraging its established European medical infrastructure, Tilray aims to dominate the physician-led distribution model that Schedule III mandates.

Earnings Preview: What to Watch

Wall Street expects Tilray to report a loss of 20 cents per share and quarterly revenue of $210.95 million, according to estimates from Benzinga Pro. 

While the beverage and international cannabis segments showed strength in Q1, the Q2 call will be scrutinized for guidance on U.S. infrastructure investment and potential tax relief.   

Investors are weighing whether Tilray's massive $265 million cash pile will be deployed to pursue rapid M&A, or whether high interest rates and domestic cannabis competition will force a more conservative rollout.

Read Next: 

• Maduro Down, Drone Stocks Up After Venezuela Mission

Photo: Shutterstock